Background

• Previous clinical studies with pegylated IFNs only investigated 48 weeks

• No prospective studies of the efficacy and safety of ribavirin doses have been conducted

• Therefore no evidence-based recommendation could be made

Previous slide

Next slide

Back to first slide

View graphic version